09:42 AM EDT, 05/29/2024 (MT Newswires) -- Intelligent Bio Solutions ( INBS ) said Wednesday it has completed recruitment and started subject screening for a pharmacokinetic study of its intelligent fingerprinting drug screening system, a non-invasive drug testing technology.

The company said it expects to complete subject screening in June.

The study, which is part of the process to get US Food and Drug Administration 510(k) regulatory approval, is aimed at providing a more detailed understanding of opiate metabolism and excretion, specifically in human sweat, the company said.

The company's drug screening system includes a drug screening cartridge, a DSR-Plus fluorescence reader, and a collection kit for laboratory analysis, Intelligent Bio said.

Price: 2.34, Change: +0.02, Percent Change: +0.86